Seonix Bio announced findings from a study published in Ophthalmology suggesting that the polygenic risk score (PRS) underlying its SightScore test may help predict glaucoma risk, disease progression, and the likelihood of surgery.
According to a company press release, SightScore uses a saliva sample to assess genetic risk for glaucoma. Developed using genetic data from more than 6.5 million individuals, the PRS was evaluated across independent cohorts representing major ancestry groups. The findings suggest that genetic risk information, used alongside clinical assessments, could help clinicians identify higher-risk patients earlier and guide monitoring and treatment decisions.
Across three validation datasets, people in the highest 10% of genetic risk had approximately 100 times the odds of glaucoma compared with those in the lowest 10%. In a population-based study, the highest-risk group reached a 3% glaucoma prevalence more than 25 years earlier than the lowest-risk group.
The PRS demonstrated predictive value across European, African, East Asian, South Asian, and Latino ancestry groups. In a US African American cohort, individuals in the highest-risk 10% had 3.8 times the odds of glaucoma compared with the remainder of the cohort. Adding the PRS to models incorporating age, sex, and eye pressure also improved glaucoma prediction in US European-, Latino-, and African-ancestry cohorts.
The study also examined longitudinal clinical outcomes among individuals with suspected or early-stage glaucoma. In a prospective cohort of 1,215 participants, 24% of those in the highest PRS decile had undergone glaucoma surgery by age 80, compared with none in the lowest decile. Higher PRS was also associated with retinal nerve fiber layer loss and an increased likelihood of treatment initiation or escalation within three years.
According to Seonix Bio, the findings suggest that genetic testing could help identify patients who may benefit from closer monitoring or earlier specialist evaluation, while potentially supporting less intensive surveillance for those at lower risk. The company emphasized that the PRS is intended to complement, rather than replace, clinical judgment and established assessments. GP







